Unique ID issued by UMIN | UMIN000057024 |
---|---|
Receipt number | R000065146 |
Scientific Title | Evaluation of the effect of remimazolam on A-delta fiber-selective nociceptive evoked potentials. |
Date of disclosure of the study information | 2025/02/17 |
Last modified on | 2025/02/13 23:11:47 |
Evaluation of the effect of remimazolam on A-delta fiber-selective nociceptive evoked potentials.
Evaluation of the effect of remimazolam on A-delta fiber-selective nociceptive evoked potentials.
Evaluation of the effect of remimazolam on A-delta fiber-selective nociceptive evoked potentials.
Evaluation of the effect of remimazolam on A-delta fiber-selective nociceptive evoked potentials.
Japan |
Patients undergoing general anesthesia
Anesthesiology |
Others
NO
To evaluate the effect of remimazolam on evoked potentials by measuring A-delta fiber-selective nociceptive evoked potentials using an intraepidermal stimulating electrode and comparing evoked potential amplitudes before and after remimazolam use.
Efficacy
Amplitude of nociceptive evoked potentials
Latency of nociceptive evoked potentials, NRS, BIS index, MOAA/S
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
Using a simulation model, set the continuous intravenous infusion rate so that the effect site concentration from continuous intravenous remimazolam infusion is (1) 0.2 micro g/ml and (2) 0.5 micro g/ml according to the age, height, and weight of the patient. The induction dose of remimazolam in the package insert should not exceed 12 mg/kg/hour.
20 | years-old | <= |
Not applicable |
Male and Female
(i) Patients 20 years of age or older at the time of obtaining consent
(ii) Patients undergoing general anesthesia with remimazolam
(iii) Patients who have given a full explanation of their participation in this study and who have given written consent based on their own free will.
(1) Patients with ASA-PS of 3 or higher
(2) Patients undergoing surgery for malignant tumors, and patients for whom the site of electrode application is the surgical site
(3) Patients diagnosed with diabetes, dementia, or epilepsy
(4) Patients with a pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator
(5) Patients with skin lesions or numbness at the electrode site
(6) Patients with communication difficulties (e.g., non-Japanese speakers, patients with mental retardation, patients with consciousness disorders)
(7) Pregnant patients
(8) Patients with allergy to remimazolam or other benzodiazepines
(9) Other patients who are judged by the investigator to be difficult to conduct the study.
20
1st name | Kunihiro |
Middle name | |
Last name | Mitsuzawa |
Shinshu University School of Medicine
The Department of Anesthesiology and Resuscitology
390-8621
3-1-1 Asahi, Matsumoto City, Nagano
0263-37-2670
mitsukuni@shinshu-u.ac.jp
1st name | Kunihiro |
Middle name | |
Last name | Mitsuzawa |
Shinshu University School of Medicine
The Department of Anesthesiology and Resuscitology
390-0807
3-1-1 Asahi, Matsumoto City, Nagano
09088009282
mitsukuni@shinshu-u.ac.jp
Shinshu University
Self funding
Self funding
Shinshu University School of Medicine Ethics Committee for Research in Life Sciences and Medicine
3-1-1 Asahi, Matsumoto City, Nagano
0263-37-2572
mdrinri@shinshu-u.ac.jp
NO
2025 | Year | 02 | Month | 17 | Day |
Unpublished
Preinitiation
2025 | Year | 01 | Month | 04 | Day |
2025 | Year | 02 | Month | 17 | Day |
2026 | Year | 12 | Month | 31 | Day |
2025 | Year | 02 | Month | 13 | Day |
2025 | Year | 02 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065146